-- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Loss $-0.49
4:15PM ET 5/05/2022 MT Newswires...
Quotes Snapshot > CLDX
Celldex Therapeutics Inc CLDX:NASDAQ
Last Price$27.00NASDAQ Previous Close - Last Trade as of 3:58PM ET 5/24/22
Today's Change-2.62(8.85%)
Bid (Size)$24.90 (2)
Ask (Size)$28.00 (144)
Day Low / High$25.17 - 29.31
Volume1.0 M
Read more news Recent News
-- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $0.2M
4:14PM ET 5/05/2022 MT Newswires...
-- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Reports Q4 Revenue $0.3M
4:06PM ET 2/28/2022 MT Newswires...
-- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Reports Q4 Loss $-0.43
4:05PM ET 2/28/2022 MT Newswires...
View all Commentary and Analysis
Celldex Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
1:12AM ET 3/01/2022 Seeking AlphaCelldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript
8:57PM ET 2/28/2022 Seeking AlphaCelldex Therapeutics (CLDX) Investor Presentation - Slideshow
1:32PM ET 2/17/2022 Seeking AlphaCelldex: Pipeline Of Drug Candidates Is Worth A Look
3:50AM ET 2/01/2022 Seeking AlphaCompany Profile
Business DescriptionCelldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ. View company web site for more details
| Address | Perryville III Building Hampton, New Jersey 08827 |
| Phone | +1.908.200.7500 |
| Number of Employees | 137 |
| Recent SEC Filing | 05/05/2022 8-K |
| President, Chief Executive Officer & Director | Anthony S. Marucci |
| CFO, Secretary, Treasurer & Senior Vice President | Sam Martin |
| Chief Scientific Officer & Executive VP | Tibor Keler |
| Chief Medical Officer & Senior Vice President | Diane C. Young |
Company Highlights
| Price Open | $29.31 |
| Previous Close | $29.62 |
| 52 Week Range | $25.17 - 57.20 |
| Market Capitalization | $1.3 B |
| Shares Outstanding | 46.8 M |
| Sector | Health Technology |
| Industry | Medical Specialties | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.69 |
| Beta vs. S&P 500 | N/A |
| Revenue | $9.5 M |
| Net Profit Margin | -1,860.01% |
| Return on Equity | -21.45% |
Analyst Ratings as of 09/16/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |